-       Report 
   - November 2025
    -  193 Pages 
    Global
   
   From       €5249EUR$5,850USD£4,607GBP 
                  -       Drug Pipelines 
   - April 2025
    -  60 Pages 
    Global
   
   From       €1436EUR$1,600USD£1,260GBP 
      €1795EUR$2,000USD£1,575GBP 
                -       Report 
   - September 2025
    -  300 Pages 
    Global
   
   From       €4482EUR$4,995USD£3,934GBP 
                  -       Report 
   - June 2024
    -  200 Pages 
    Global
   
   From       €5707EUR$6,360USD£5,009GBP 
      €7134EUR$7,950USD£6,261GBP 
                  -       Report 
   - January 2022
    -  60 Pages 
    Global
   
   From       €2836EUR$3,160USD£2,489GBP 
      €3544EUR$3,950USD£3,111GBP 
                   -       Report 
   - January 2024
    -  150 Pages 
    Global
   
   From       €3455EUR$3,850USD£3,032GBP 
      €4352EUR$4,850USD£3,820GBP 
                -       Report 
   - October 2024
    -  89 Pages 
    Global
   
   From       €3500EUR$4,178USD£3,179GBP 
                      Dermatophytic Onychomycosis (DO) is a fungal infection of the nail caused by dermatophytes. It is the most common type of onychomycosis, accounting for up to 50% of all nail infections. Treatment of DO typically involves the use of antifungal drugs, such as terbinafine, itraconazole, and fluconazole. These drugs are typically administered orally or topically, depending on the severity of the infection.
Infectious Diseases Drugs are a class of drugs used to treat a wide range of infectious diseases,    including DO. These drugs are typically prescribed by a physician and are available in both generic and brand-name formulations. Commonly prescribed Infectious Diseases Drugs include antibiotics, antivirals, antifungals, and antiparasitics.
Some companies in the Dermatophytic Onychomycosis Drug market include Pfizer, Merck, Novartis, and Johnson & Johnson. Show Less   Read more